AI-Designed Caffeine Off‑Switch Controls Engineered Cells

Overview

• Texas A&M researchers report CODS, a caffeine-operated dissociation system created with AI-guided de novo protein design that uses a synthetic mini-binder to separate engineered protein complexes inside living cells.
• The team demonstrated CODS can sharply reduce gene-circuit activity, trigger programmed inflammatory cell death (pyroptosis) by freeing gasdermin D, and temporarily silence CAR T‑cell activity in laboratory tests.
• CODS responds to low caffeine concentrations, acts within minutes and is repeatedly reversible when caffeine is added or removed, giving a rapid, recoverable 'pause' rather than a permanent shutdown.
• The authors have filed a provisional patent covering CODS and say the platform still needs testing in therapeutic cell formats, animal models, and disease-relevant settings before any clinical use is considered.
• The work highlights how AI and high-performance computing can produce new molecular control tools and raises practical translation questions about dosing, in vivo pharmacokinetics, safety testing, and how a familiar small molecule could improve the safety of engineered-cell therapies for patients.